Development of a DNA-launched replicon as a vaccine for porcine reproductive and respiratory syndrome virus

Sujit Pujhari, Tayyba T. Baig, Satynder Hansra, Alexander N. Zakhartchouk

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Though a modified live attenuated vaccine (MLV) is available against porcine reproductive and respiratory syndrome virus (PRRSV), its limitations in protective efficacy, safety and few others warrant the development of newer vaccines. In this study, we have constructed a propagation-defective DNA-launched PRRSV replicon as a vaccine candidate and evaluated its immunogenicity and protective efficacy in a group of pigs along with MLV vaccinated group. Our data showed that prior to the intranasal challenge with a homologous strain of PRRSV, only MLV vaccinated pigs developed antibody response measured by ELISA and none of the pigs in any group developed PRRSV neutralizing antibodies in serum. The MLV vaccinated group also showed high PRRSV-specific INF-γ response, whereas the replicon-vaccinated pigs showed low but detectable INF-γ response. After 14 days post challenge, all groups showed similar PRRSV-specific serum neutralizing titers and were positive for PRRSV-specific ELISA antibody. In addition, the replicon-vaccinated group showed a significant reduction in viremia in comparison to the control group. In conclusion, vaccination with the PRRSV DNA-launched replicon decreased the viremia and viral load in bronchoalveolar lavage fluids of the PRRSV-challenged pigs and increased numbers of IFN-γ producing cells. Thus, the vaccine is partially protective and is a potential vaccine candidate for future with further improvement. The possible means of improvement is the expression of immunostimulatory genes by the replicon. We demonstrated the feasibility of this approach by expression of a foreign gene encoding firefly luciferase after transfection of cultured cells with the replicon plasmid DNA.

Original languageEnglish (US)
Pages (from-to)321-326
Number of pages6
JournalVirus Research
Volume173
Issue number2
DOIs
StatePublished - May 1 2013

Fingerprint

Porcine respiratory and reproductive syndrome virus
Replicon
Vaccines
DNA
Attenuated Vaccines
Swine
Viremia
Enzyme-Linked Immunosorbent Assay
Firefly Luciferases
Bronchoalveolar Lavage Fluid
Neutralizing Antibodies
Viral Load
Serum
Antibody Formation
Transfection
Cultured Cells
Vaccination
Plasmids
Safety
Gene Expression

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Virology
  • Infectious Diseases

Cite this

Pujhari, Sujit ; Baig, Tayyba T. ; Hansra, Satynder ; Zakhartchouk, Alexander N. / Development of a DNA-launched replicon as a vaccine for porcine reproductive and respiratory syndrome virus. In: Virus Research. 2013 ; Vol. 173, No. 2. pp. 321-326.
@article{a996b812c3a84c6bb6f1080af87ae054,
title = "Development of a DNA-launched replicon as a vaccine for porcine reproductive and respiratory syndrome virus",
abstract = "Though a modified live attenuated vaccine (MLV) is available against porcine reproductive and respiratory syndrome virus (PRRSV), its limitations in protective efficacy, safety and few others warrant the development of newer vaccines. In this study, we have constructed a propagation-defective DNA-launched PRRSV replicon as a vaccine candidate and evaluated its immunogenicity and protective efficacy in a group of pigs along with MLV vaccinated group. Our data showed that prior to the intranasal challenge with a homologous strain of PRRSV, only MLV vaccinated pigs developed antibody response measured by ELISA and none of the pigs in any group developed PRRSV neutralizing antibodies in serum. The MLV vaccinated group also showed high PRRSV-specific INF-γ response, whereas the replicon-vaccinated pigs showed low but detectable INF-γ response. After 14 days post challenge, all groups showed similar PRRSV-specific serum neutralizing titers and were positive for PRRSV-specific ELISA antibody. In addition, the replicon-vaccinated group showed a significant reduction in viremia in comparison to the control group. In conclusion, vaccination with the PRRSV DNA-launched replicon decreased the viremia and viral load in bronchoalveolar lavage fluids of the PRRSV-challenged pigs and increased numbers of IFN-γ producing cells. Thus, the vaccine is partially protective and is a potential vaccine candidate for future with further improvement. The possible means of improvement is the expression of immunostimulatory genes by the replicon. We demonstrated the feasibility of this approach by expression of a foreign gene encoding firefly luciferase after transfection of cultured cells with the replicon plasmid DNA.",
author = "Sujit Pujhari and Baig, {Tayyba T.} and Satynder Hansra and Zakhartchouk, {Alexander N.}",
year = "2013",
month = "5",
day = "1",
doi = "10.1016/j.virusres.2013.01.011",
language = "English (US)",
volume = "173",
pages = "321--326",
journal = "Virus Research",
issn = "0168-1702",
publisher = "Elsevier",
number = "2",

}

Development of a DNA-launched replicon as a vaccine for porcine reproductive and respiratory syndrome virus. / Pujhari, Sujit; Baig, Tayyba T.; Hansra, Satynder; Zakhartchouk, Alexander N.

In: Virus Research, Vol. 173, No. 2, 01.05.2013, p. 321-326.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Development of a DNA-launched replicon as a vaccine for porcine reproductive and respiratory syndrome virus

AU - Pujhari, Sujit

AU - Baig, Tayyba T.

AU - Hansra, Satynder

AU - Zakhartchouk, Alexander N.

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Though a modified live attenuated vaccine (MLV) is available against porcine reproductive and respiratory syndrome virus (PRRSV), its limitations in protective efficacy, safety and few others warrant the development of newer vaccines. In this study, we have constructed a propagation-defective DNA-launched PRRSV replicon as a vaccine candidate and evaluated its immunogenicity and protective efficacy in a group of pigs along with MLV vaccinated group. Our data showed that prior to the intranasal challenge with a homologous strain of PRRSV, only MLV vaccinated pigs developed antibody response measured by ELISA and none of the pigs in any group developed PRRSV neutralizing antibodies in serum. The MLV vaccinated group also showed high PRRSV-specific INF-γ response, whereas the replicon-vaccinated pigs showed low but detectable INF-γ response. After 14 days post challenge, all groups showed similar PRRSV-specific serum neutralizing titers and were positive for PRRSV-specific ELISA antibody. In addition, the replicon-vaccinated group showed a significant reduction in viremia in comparison to the control group. In conclusion, vaccination with the PRRSV DNA-launched replicon decreased the viremia and viral load in bronchoalveolar lavage fluids of the PRRSV-challenged pigs and increased numbers of IFN-γ producing cells. Thus, the vaccine is partially protective and is a potential vaccine candidate for future with further improvement. The possible means of improvement is the expression of immunostimulatory genes by the replicon. We demonstrated the feasibility of this approach by expression of a foreign gene encoding firefly luciferase after transfection of cultured cells with the replicon plasmid DNA.

AB - Though a modified live attenuated vaccine (MLV) is available against porcine reproductive and respiratory syndrome virus (PRRSV), its limitations in protective efficacy, safety and few others warrant the development of newer vaccines. In this study, we have constructed a propagation-defective DNA-launched PRRSV replicon as a vaccine candidate and evaluated its immunogenicity and protective efficacy in a group of pigs along with MLV vaccinated group. Our data showed that prior to the intranasal challenge with a homologous strain of PRRSV, only MLV vaccinated pigs developed antibody response measured by ELISA and none of the pigs in any group developed PRRSV neutralizing antibodies in serum. The MLV vaccinated group also showed high PRRSV-specific INF-γ response, whereas the replicon-vaccinated pigs showed low but detectable INF-γ response. After 14 days post challenge, all groups showed similar PRRSV-specific serum neutralizing titers and were positive for PRRSV-specific ELISA antibody. In addition, the replicon-vaccinated group showed a significant reduction in viremia in comparison to the control group. In conclusion, vaccination with the PRRSV DNA-launched replicon decreased the viremia and viral load in bronchoalveolar lavage fluids of the PRRSV-challenged pigs and increased numbers of IFN-γ producing cells. Thus, the vaccine is partially protective and is a potential vaccine candidate for future with further improvement. The possible means of improvement is the expression of immunostimulatory genes by the replicon. We demonstrated the feasibility of this approach by expression of a foreign gene encoding firefly luciferase after transfection of cultured cells with the replicon plasmid DNA.

UR - http://www.scopus.com/inward/record.url?scp=84876878495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876878495&partnerID=8YFLogxK

U2 - 10.1016/j.virusres.2013.01.011

DO - 10.1016/j.virusres.2013.01.011

M3 - Article

C2 - 23353778

AN - SCOPUS:84876878495

VL - 173

SP - 321

EP - 326

JO - Virus Research

JF - Virus Research

SN - 0168-1702

IS - 2

ER -